Five ERC Starting Grants for Helmholtz Munich

Five prestigious Starting Grants from the European Research Council have been granted to researchers with Helmholtz Munich as the host institution. The funding will enable scientists at Helmholtz Munich to advance innovative projects across various areas, including phage therapy and epigenetics. With a total of 60 acquired ERC Grants, Helmholtz Munich stands out as a leading research center of excellence in Europe.

Background Research:

1. Helmholtz Munich: Also known as the ‚Helmholtz Zentrum München‘, it is a member of the Helmholtz Association of German Research Centres and is dedicated to environmental health studies. It combines various disciplines to explore how external and lifestyle factors interact with personal genetic background leading to disease.

2. ERC Starting Grants: Offered by European Research Council, these grants are meant to support up-and-coming research leaders who are at the career stage at which they are commencing their own independent research team or programme.

3. Phage Therapy: This refers to the therapeutic use of bacteriophages (type of virus) for treatment of bacterial infections.

4. Epigenetics: Concerns changes in organisms brought about by modification in gene expression rather than alteration in genetic code itself.

FAQs:

1. What is Helmholtz Munich?
Helmholtz Munich, officially referred as ‚Helmholtz Zentrum München‘, is a german medical research center that concentrates on environment-related health issues. They combine several scientific disciplines such as biology, environmental science and medicine, pursuing the collective goal of healthier lives within an aging society.

2.What have these researchers achieved?
The Researchers at Helmholtz Munich have been awarded five Starting Grants from the esteemed European Research Council (ERC). These grants provide them with significant funding, thereby enabling them advance various innovative projects which particularly include phage therapy and epigenetic work among others.

3.What are these ERC Starting Grants?
ERC’s Starting Grants give promising scientists across Europe financial backing to help kick-start their research programs independently developing their teams or intensifying progression on already flagged-off programs in an inventive way that could eventually lead into transformational breakthroughs enhancing human knowledge base substantially.

4.How many total ERC grants has Helmholtz Munich received so far?
So far,Helmholtz Munich has successfully acquired a total of 60 ERC grants, thus positioning it among the leading research centers of excellence across Europe.

5.What are Phage therapy and epigenetics?
Phage therapy is a potential treatment for bacterial infections. It uses bacteriophages which are viruses specifically designed to infect and kill bacteria. Epigenetics includes changes in an organism that occur through modification in gene expression and not any alteration in genetic code itself. This field recognizes the impact of outside factors like our lifestyle choices or environmental factors on how our genes work.

6.What does this mean for Helmholtz Munich?
This achievement establishes Helmholtz Munich as a vibrant hub of cutting-edge scientific research.It gives them an edge for attracting best talents globally while emphasizing the enormous contribution they give to the scientific community particularly within Europe underlining their consistent pursuit towards excellence time & again.

Originamitteilung:

Five prestigious Starting Grants from the European Research Council have been granted to researchers with Helmholtz Munich as the host institution. The funding will enable scientists at Helmholtz Munich to advance innovative projects across various areas, including phage therapy and epigenetics. With a total of 60 acquired ERC Grants, Helmholtz Munich stands out as a leading research center of excellence in Europe.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

ERC Consolidator Grant für Georg Winter gibt rasant wachsendem Forschungsfeld weiteren Auftrieb

Maßgeschneiderte kleine Moleküle, die sich an Krebs verursachende Proteine heften und Tumorzellen dadurch unschädlich machen – das ist Georg Winters Spezialgebiet, in dem sich der Forschungsgruppenleiter am CeMM der ÖAW als weltweit führender Experten etabliert hat. Sein neuestes ERC CoG Projekt GENEomorph hebt seine Forschung auf eine neue Ebene: Anstatt Krebsproteine wie bisher für die zelluläre Müllabfuhr zu markieren, nimmt Winter mit seinen Design-Molekülen nun sogenannte Transkriptionsfaktoren ins Visier, ein vielversprechender Weg für neue Medikamente. Das sieht auch der Europäische Forschungsrat ERC so: Er fördert dieses Projekt in den nächsten fünf Jahren mit 1,9 Millionen Euro.

Read More